Evaluating Daphnetin Capsule for Treating Vascular Cognitive Impairment Without Dementia A Randomized, Double-Blind, Placebo-Controlled Study

What this Trial Is About

Researchers are evaluating the clinical efficacy and safety of Daphnetin Capsules in patients with vascular cognitive impairment without dementia VCI-ND. This condition results from strokes and other cerebrovascular diseases, causing problems with memory and thinking. The study aims to explore whether Daphnetin, which has neurovascular protective effects, can improve cognitive status, as there is currently a lack of high-quality evidence for its use in this condition. Participants will be randomly assigned to take either oral Daphnetin Capsules or a placebo three times a day for six months. This is a double-blind, placebo-controlled study following the international FINESSE framework. Follow-up visits and case report form completions will occur every three months during the study period. During the trial, participants will undergo various cognitive and functional assessments, including the Vascular Dementia Assessment Scale-cognitive subscale VADAS-cog at six months as the primary outcome. Secondary measures include stroke incidence, dementia onset, mental state evaluations, daily living activities, motor function, and quality of life questionnaires. The study will monitor safety and efficacy throughout the six-month treatment and follow-up periods, with total participation lasting six months.

Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia